National report - The benefits of Allergan's proposed oral psoriasis drug, Tazoral, do not outweigh possible risks of birth defects and bone loss, a U.S. Food and Drug Administration advisory panel has decided.
Study Reports High Frequency of Emergency Complications During Dermatological, Surgical, and Cosmetic Procedures
The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition
Exploring the Intersection of Permanent Makeup and Dermatology
The Cutaneous Connection: Cosmetic Dermatology: Procedures and Practice
Facial Redness Reduction Cosmetics
Hands-on Workshop Empowers Clinicians in Cosmetic Dermatology